Assessing primary non-adherence for newer glucose lowering medications for patients with type 2 diabetes

PI(s): Jing Luo, MD, MPH

Purpose: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are newer glucose lowering medications approved for the treatment of type 2 diabetes. Studies describing the patterns of selection, electronic prescribing and filling (medication adherence) of GLP1-RA and SGLT2i’s are extremely limited. Furthermore, the prevalence of primary non-adherence to these classes have not been previously described.

Goal(s): To measure primary non-adherence to GLP1-RA and SGLT2i for patients enrolled in a UPMC health plan.

Study Design: Retrospective cohort study

PaTH Partners:

  • UPMC/UPMC Health Plan
  • University of Pittsburgh


How to Participate: Researchers will use electronic health record and insurance claims data from the UPMC.

PaTH Network Logo
Twitter Logo Facebook Logo LinkedIn Logo YouTube Logo

Copyright 2016 | PaTH Network